Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-16
2000-02-01
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514263, 544267, 544272, 544277, A61K 3152, C07D47300
Patent
active
060203374
ABSTRACT:
Therapeutic compounds, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, having a formula: ##STR1## wherein R.sub.0 is selected from the group consisting of hydrogen, halo, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, wherein the substituents of substituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl are other than halo; n is an integer from one to sixteen; R.sub.1, R.sub.2, and R.sub.3 are independently selected from the group consisting of a halo; haloacetoxy; hydrogen; hydroxy; oxo; --N.dbd.C.dbd.S; --N.dbd.C.dbd.O; --0--C.tbd.N; --C.tbd.N; --N.dbd.N.dbd.N; and --C--(R.sub.5).sub.3, R.sub.5 being independently a halo or hydrogen, at least one R.sub.5 being halo, at least one of R.sub.1, R.sub.2, and R.sub.3 being halo, cyano, isocyano, isothiocyano, azide or haloacetoxy group; R.sub.4 is hydrogen, C.sub.(1-6) alkyl, C.sub.(1-6) alkenyl, cyclo C.sub.(4-6) alkyl, or phenyl; one or more hydrogen atoms of (CH.sub.2).sub.n --CH.sub.a --CH.sub.b --CH.sub.c may be replaced with: i) at least one of halogen atom, hydroxyl, oxo, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyalkyl, or C.sub.(2-10) alkenyl; or ii) one or more unsaturated bonds; and any two adjacent carbon atoms of (CH.sub.2).sub.n --CH.sub.a --CH.sub.b --CH.sub.c may be instead separated by at least one oxygen atom. These compounds are useful in treating or preventing diseases by inhibiting selective second messenger pathways.
REFERENCES:
patent: 3422107 (1969-01-01), Mohler et al.
patent: 3737433 (1987-03-01), Mohler et al.
patent: 4289776 (1981-09-01), Mohler et al.
patent: 4515795 (1985-05-01), Hinze et al.
patent: 4576947 (1986-03-01), Hinze et al.
patent: 4636507 (1987-01-01), Kreutzer et al.
patent: 4766142 (1988-08-01), Arcomone et al.
patent: 4833146 (1989-05-01), Gerbert et al.
patent: 4952679 (1990-08-01), Hoegerle et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 5039666 (1991-08-01), Novick et al.
patent: 5086056 (1992-02-01), Janssens et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5126349 (1992-06-01), Deford et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5521315 (1996-05-01), Underiner et al.
patent: 5670506 (1997-09-01), Leigh et al.
Kanehira et al., Chemicals Abstracts 110: 212848x, p. 757, 1989.
Salikhov et al., Chemical Abstracts 112: 157941m, 1990.
Kanehira et al., Chemical Abstracts 110:212848x p. 757, 1989.
Salikhov et al., Chemical Abstracts 112: 157941m. 1990.
Bianco et al., Blood, 76: Supplement 1 (522), p. 133a "Pentoxifylline (PTX) and GM-CSF Decrease Tumor Necrosis Factor-ALPHA (TNF-.alpha.) Levels in Patients Undergoing Allogeneic Bone Marrow Transplantation (BMT)", 1991.
Bryce et al., Arzneim-Forsch./Drug Res., 39:4, pp. 512-517. "Metabolism and Pharmacokinetics of .sup.14 C-Pentoxifylline in Healthy volunteers", 1989.
Davis et al., Applied Environment Microbial., 48:2, pp. 327-331, "Microbial Models of Mammalian Metobolism: Microbial Reductiona nd Oxidation of Pentoxifylline", Aug. 1984.
Sahkhov et al., Abstract 112:157941m, 1990.
Akhrem et al., Khimigetero Soedin (1979) 2, pp. 230-234.
Klein J. Peter
Kumar Anil M.
Leigh Alistair J.
Michnick John
Underiner Gail
Cell Therapeutics Inc.
Shah Mukund J.
Sripada Pavanaram K
LandOfFree
Electronegative-substituted long chain xanthine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Electronegative-substituted long chain xanthine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Electronegative-substituted long chain xanthine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-937710